Table 3

Prevention of breast events.

Outcome

Studies

Participants

Risk Ratio (M-H, Fixed, 95% CI), I2


Tamoxifen (10 or 20 mg daily) versus no therapy/placebo

Prevention of gynecomastia

• at 3 months

Fradet 2007

94

0.06 (0.01, 0.43), -

• at 6 months

Fradet 2007, Perdona 2005

195

0.10 (0.05, 0.22), 0%

• at 9 to 12 months

Boccardo 2005, Fradet 2007

171

0.17 (0.09, 0.31), 0%

Prevention of breast pain

• at 3 months

Fradet 2007, Saltzstein 2005

165

0.09 (0.03, 0.24), 74%a

• at 6 months

Fradet 2006, Perdona 2005

195

0.06 (0.02, 0.17), 27%

• at 9 to 12 months

Boccardo 2005, Fradet 2007

171

0.13 (0.06, 0.27), 0%


Tamoxifen (20 mg daily) versus anastrozole (1 mg daily)

Prevention of gynecomastia

• median 12 months

Boccardo 2005

73

0.22 (0.08, 0.58), -

Prevention of breast pain

• median 12 months

Boccardo 2005, Saltzstein 2005

143

0.25 (0.10, 0.64), 0%


Tamoxifen (10 mg daily) versus radiotherapy

Prevention of gynecomastia

• at 6 months

Perdona 2005

100

0.24 (0.09, 0.65), -

Prevention of breast pain

• at 6 months

Perdona 2005

100

0.20 (0.06, 0.65), -


aRisk ratio with random effects model (M-H, 95% CI) 0.10 (0.01 to 0.90).

Kunath et al. BMC Medicine 2012 10:96   doi:10.1186/1741-7015-10-96

Open Data